CD4 and neoplasm: The shIDO-ST + ICB treated tumors have significantly higher numbers of tumor-infiltrating CD4+ and CD8+ T cells compared to all other treatment groups (p < 0.0001), as well as significantly higher numbers of CD11c+ cells (Figure 6A).